Context Therapeutics Inc. CNTX
0.21 USD +0.01 (+6.70%)
Nov 4, 2026, 2:37 PM EST
0.199 Day range 0.2098
0.189 52-week range 3.62
- YTD
- -85.92%
- 1 year
- -81.35%
Analyst view
Price target (mean) 7.70 +3619.8% upside
Now 0.207
- Target (low)
- 4.50
- Target (mean)
- 7.70
- Target (high)
- 10.00
Ratings (0m) 5 5 buy · 0 hold · 0 sell
- Strong buy3
- Buy2
- Hold0
- Sell0
- Strong sell0
Recommendation trend
- This month 5
- 1 month ago 5
- 2 months ago 4
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.05 | -0.06 – -0.04 | -0.42 | +88.1% | 0 | 0.0% | 4 |
| Next quarter | -0.06 | -0.06 – -0.06 | -0.23 | +73.9% | 0 | 0.0% | 1 |
| Current year | -0.51 | -0.53 – -0.49 | -1.50 | +66.0% | 0 | 0.0% | 4 |
| Next year | -0.3025 | -0.37 – -0.24 | -0.51 | +40.7% | 0 | 0.0% | 5 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 25, 2024 | D. Boral Capital | Initiated | — | Buy |
| Sep 23, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Sep 16, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Jul 10, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| May 16, 2024 | Piper Sandler | Initiated | — | Overweight |
| May 9, 2024 | HC Wainwright & Co. | Maintained | Buy | Buy |
| May 9, 2024 | Maxim Group | Maintained | Buy | Buy |
| Mar 21, 2024 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Nov 1, 2023 | HC Wainwright & Co. | Upgrade | Neutral | Buy |
| Sep 11, 2023 | Maxim Group | Initiated | — | Buy |
| Jun 6, 2023 | HC Wainwright & Co. | Reiterated | — | Neutral |
| Mar 23, 2023 | HC Wainwright & Co. | Downgrade | Buy | Neutral |
| Feb 7, 2023 | HC Wainwright & Co. | Reiterated | — | Buy |
| Feb 2, 2022 | HC Wainwright & Co. | Initiated | — | Buy |
| Jan 24, 2022 | ThinkEquity | Initiated | — | Buy |